Abstract
Mantle cell lymphoma is characterized by a genetic translocation results in aberrant overexpression of the CCND1 gene, which encodes cyclin D1. This protein functions as a regulator of the cell cycle progression, hence is considered to play an important role in the pathogenesis of the disease. In this study, we used RNA interference strategies to examine whether cyclin D1 might serve as a therapeutic target for mantle cell lymphoma. Knocking down cyclin D1 resulted in significant growth retardation, cell cycle arrest, and most importantly, induction of apoptosis. These results mark cyclin D1 as a target for mantle cell lymphoma and emphasize the therapeutic potential hidden in its silencing.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Apoptosis
-
Cell Cycle
-
Cell Line, Tumor
-
Cell Proliferation
-
Cell Survival
-
Cyclin D1 / metabolism*
-
DEAD-box RNA Helicases / metabolism
-
Gene Expression Regulation, Neoplastic*
-
Gene Silencing
-
Humans
-
Lymphoma, Mantle-Cell / therapy*
-
RNA / metabolism
-
RNA Interference*
-
Ribonuclease III / metabolism
Substances
-
Antineoplastic Agents
-
Cyclin D1
-
RNA
-
DICER1 protein, human
-
Ribonuclease III
-
DEAD-box RNA Helicases
Grants and funding
This work was supported by grants from the Lewis Family Trust and Israel Science Foundation (
www.isf.org.il) (Award #181/10) to DP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.